Deep intramuscular methylprednisolone treatment of recurrent scleritis
To evaluate the efficacy of deep intramuscular methylprednisolone (IMMP) in the treatment of recurrent scleritis. A total of 15 patients with scleritis (12 anterior, 3 pan) underwent IMMP injection deep into the thigh. Thirteen patients were already being treated with oral non-steroidal anti-inflamm...
Gespeichert in:
| Veröffentlicht in: | Ocular immunology and inflammation 2005-02, Vol.13 (1), p.67-71 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 71 |
|---|---|
| container_issue | 1 |
| container_start_page | 67 |
| container_title | Ocular immunology and inflammation |
| container_volume | 13 |
| creator | Deokule, Sunil Saeed, Tariq Murray, Philip I |
| description | To evaluate the efficacy of deep intramuscular methylprednisolone (IMMP) in the treatment of recurrent scleritis.
A total of 15 patients with scleritis (12 anterior, 3 pan) underwent IMMP injection deep into the thigh. Thirteen patients were already being treated with oral non-steroidal anti-inflammatory drugs, oral prednisolone, an oral immunosuppressive agent, or a combination of these drugs. A second IMMP injection was given to nine patients, making a total of 24 injections. Follow-up ranged from 4 to 18 months.
There was a documented improvement in scleritis after 21/24 (87.3%) injections with a mean duration of improvement of 5.7 months. No patient required the introduction of oral corticosteroid or immunosuppressive agent, and only one patient required an increase in methotrexate to control the disease. No systemic, injection site, or ocular side effects were noted.
Deep IMMP is a safe and effective treatment for scleritis. It ensures compliance, avoids the systemic side effects of oral corticosteroids, and is easily repeatable in the outpatient setting. |
| doi_str_mv | 10.1080/09273940490518919 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_67699750</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67699750</sourcerecordid><originalsourceid>FETCH-LOGICAL-p209t-71c32b4a1b0c6fe0af5dd38ef8a7040c50cacb7aea2dd846cf9ad01936e2ad613</originalsourceid><addsrcrecordid>eNo1jz9PwzAUxD2AaCl8ABaUiS3wbCexPaJCAakSC8zRi_0igpw_2M7Qb08qynS6u59OOsZuONxz0PAARihpCigMlFwbbs7Y-pjlS6hX7DLGb4ClNfyCrXipoVBKrNnuiWjKuiEF7OdoZ48h6yl9HfwUyA1dHP04UJYCYeppSNnYZoHsHMLRROspdKmLV-y8RR_p-qQb9rl7_ti-5vv3l7ft4z6fBJiUK26laArkDdiqJcC2dE5qajUqKMCWYNE2CgmFc7qobGvQATeyIoGu4nLD7v52pzD-zBRT3XfRkvc40DjHulKVMaqEBbw9gXPTk6un0PUYDvX_c_kLsqpbsA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67699750</pqid></control><display><type>article</type><title>Deep intramuscular methylprednisolone treatment of recurrent scleritis</title><source>MEDLINE</source><source>Taylor & Francis</source><source>Taylor & Francis Medical Library - CRKN</source><creator>Deokule, Sunil ; Saeed, Tariq ; Murray, Philip I</creator><creatorcontrib>Deokule, Sunil ; Saeed, Tariq ; Murray, Philip I</creatorcontrib><description>To evaluate the efficacy of deep intramuscular methylprednisolone (IMMP) in the treatment of recurrent scleritis.
A total of 15 patients with scleritis (12 anterior, 3 pan) underwent IMMP injection deep into the thigh. Thirteen patients were already being treated with oral non-steroidal anti-inflammatory drugs, oral prednisolone, an oral immunosuppressive agent, or a combination of these drugs. A second IMMP injection was given to nine patients, making a total of 24 injections. Follow-up ranged from 4 to 18 months.
There was a documented improvement in scleritis after 21/24 (87.3%) injections with a mean duration of improvement of 5.7 months. No patient required the introduction of oral corticosteroid or immunosuppressive agent, and only one patient required an increase in methotrexate to control the disease. No systemic, injection site, or ocular side effects were noted.
Deep IMMP is a safe and effective treatment for scleritis. It ensures compliance, avoids the systemic side effects of oral corticosteroids, and is easily repeatable in the outpatient setting.</description><identifier>ISSN: 0927-3948</identifier><identifier>DOI: 10.1080/09273940490518919</identifier><identifier>PMID: 15804772</identifier><language>eng</language><publisher>England</publisher><subject>Adult ; Aged ; Female ; Glucocorticoids - therapeutic use ; Humans ; Injections, Intramuscular ; Male ; Methylprednisolone - therapeutic use ; Middle Aged ; Recurrence ; Scleritis - drug therapy ; Treatment Outcome</subject><ispartof>Ocular immunology and inflammation, 2005-02, Vol.13 (1), p.67-71</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15804772$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Deokule, Sunil</creatorcontrib><creatorcontrib>Saeed, Tariq</creatorcontrib><creatorcontrib>Murray, Philip I</creatorcontrib><title>Deep intramuscular methylprednisolone treatment of recurrent scleritis</title><title>Ocular immunology and inflammation</title><addtitle>Ocul Immunol Inflamm</addtitle><description>To evaluate the efficacy of deep intramuscular methylprednisolone (IMMP) in the treatment of recurrent scleritis.
A total of 15 patients with scleritis (12 anterior, 3 pan) underwent IMMP injection deep into the thigh. Thirteen patients were already being treated with oral non-steroidal anti-inflammatory drugs, oral prednisolone, an oral immunosuppressive agent, or a combination of these drugs. A second IMMP injection was given to nine patients, making a total of 24 injections. Follow-up ranged from 4 to 18 months.
There was a documented improvement in scleritis after 21/24 (87.3%) injections with a mean duration of improvement of 5.7 months. No patient required the introduction of oral corticosteroid or immunosuppressive agent, and only one patient required an increase in methotrexate to control the disease. No systemic, injection site, or ocular side effects were noted.
Deep IMMP is a safe and effective treatment for scleritis. It ensures compliance, avoids the systemic side effects of oral corticosteroids, and is easily repeatable in the outpatient setting.</description><subject>Adult</subject><subject>Aged</subject><subject>Female</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Humans</subject><subject>Injections, Intramuscular</subject><subject>Male</subject><subject>Methylprednisolone - therapeutic use</subject><subject>Middle Aged</subject><subject>Recurrence</subject><subject>Scleritis - drug therapy</subject><subject>Treatment Outcome</subject><issn>0927-3948</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1jz9PwzAUxD2AaCl8ABaUiS3wbCexPaJCAakSC8zRi_0igpw_2M7Qb08qynS6u59OOsZuONxz0PAARihpCigMlFwbbs7Y-pjlS6hX7DLGb4ClNfyCrXipoVBKrNnuiWjKuiEF7OdoZ48h6yl9HfwUyA1dHP04UJYCYeppSNnYZoHsHMLRROspdKmLV-y8RR_p-qQb9rl7_ti-5vv3l7ft4z6fBJiUK26laArkDdiqJcC2dE5qajUqKMCWYNE2CgmFc7qobGvQATeyIoGu4nLD7v52pzD-zBRT3XfRkvc40DjHulKVMaqEBbw9gXPTk6un0PUYDvX_c_kLsqpbsA</recordid><startdate>200502</startdate><enddate>200502</enddate><creator>Deokule, Sunil</creator><creator>Saeed, Tariq</creator><creator>Murray, Philip I</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200502</creationdate><title>Deep intramuscular methylprednisolone treatment of recurrent scleritis</title><author>Deokule, Sunil ; Saeed, Tariq ; Murray, Philip I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p209t-71c32b4a1b0c6fe0af5dd38ef8a7040c50cacb7aea2dd846cf9ad01936e2ad613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Female</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Humans</topic><topic>Injections, Intramuscular</topic><topic>Male</topic><topic>Methylprednisolone - therapeutic use</topic><topic>Middle Aged</topic><topic>Recurrence</topic><topic>Scleritis - drug therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Deokule, Sunil</creatorcontrib><creatorcontrib>Saeed, Tariq</creatorcontrib><creatorcontrib>Murray, Philip I</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Ocular immunology and inflammation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Deokule, Sunil</au><au>Saeed, Tariq</au><au>Murray, Philip I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Deep intramuscular methylprednisolone treatment of recurrent scleritis</atitle><jtitle>Ocular immunology and inflammation</jtitle><addtitle>Ocul Immunol Inflamm</addtitle><date>2005-02</date><risdate>2005</risdate><volume>13</volume><issue>1</issue><spage>67</spage><epage>71</epage><pages>67-71</pages><issn>0927-3948</issn><abstract>To evaluate the efficacy of deep intramuscular methylprednisolone (IMMP) in the treatment of recurrent scleritis.
A total of 15 patients with scleritis (12 anterior, 3 pan) underwent IMMP injection deep into the thigh. Thirteen patients were already being treated with oral non-steroidal anti-inflammatory drugs, oral prednisolone, an oral immunosuppressive agent, or a combination of these drugs. A second IMMP injection was given to nine patients, making a total of 24 injections. Follow-up ranged from 4 to 18 months.
There was a documented improvement in scleritis after 21/24 (87.3%) injections with a mean duration of improvement of 5.7 months. No patient required the introduction of oral corticosteroid or immunosuppressive agent, and only one patient required an increase in methotrexate to control the disease. No systemic, injection site, or ocular side effects were noted.
Deep IMMP is a safe and effective treatment for scleritis. It ensures compliance, avoids the systemic side effects of oral corticosteroids, and is easily repeatable in the outpatient setting.</abstract><cop>England</cop><pmid>15804772</pmid><doi>10.1080/09273940490518919</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0927-3948 |
| ispartof | Ocular immunology and inflammation, 2005-02, Vol.13 (1), p.67-71 |
| issn | 0927-3948 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67699750 |
| source | MEDLINE; Taylor & Francis; Taylor & Francis Medical Library - CRKN |
| subjects | Adult Aged Female Glucocorticoids - therapeutic use Humans Injections, Intramuscular Male Methylprednisolone - therapeutic use Middle Aged Recurrence Scleritis - drug therapy Treatment Outcome |
| title | Deep intramuscular methylprednisolone treatment of recurrent scleritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T12%3A58%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Deep%20intramuscular%20methylprednisolone%20treatment%20of%20recurrent%20scleritis&rft.jtitle=Ocular%20immunology%20and%20inflammation&rft.au=Deokule,%20Sunil&rft.date=2005-02&rft.volume=13&rft.issue=1&rft.spage=67&rft.epage=71&rft.pages=67-71&rft.issn=0927-3948&rft_id=info:doi/10.1080/09273940490518919&rft_dat=%3Cproquest_pubme%3E67699750%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67699750&rft_id=info:pmid/15804772&rfr_iscdi=true |